Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 45

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_HPM-8-7_002

تاریخ نمایه سازی: 18 مرداد 1403

Abstract:

Background There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of ۳ psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods This has been achieved by the participation of a prospective cohort involving a total of ۹۰ moderate to severe psoriasis patients, which has been conducted at ۵ public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-۷۵ and/or body surface area (BSA)

Authors

Nor Azmaniza Azizam

Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Selangor, Malaysia

Aniza Ismail

Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Saperi Sulong

Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Norazirah Md Nor

Medical Department, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults ...
  • Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, ...
  • Ding X, Wang T, Shen Y, et al. Prevalence of ...
  • Mohd Affandi A, Ngah Saaya N, Johar A, Muneer A, ...
  • Thorleifsdottir R, Sigurdardottir S, Sigurgeirsson B, et al. Patient-reported outcomes ...
  • Ministry of Health. Management of Psoriasis Vulgaris. Kuala Lumpur; ۲۰۱۳ ...
  • Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A. ...
  • Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities ...
  • Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden ...
  • Singh S, Young P, Armstrong AW. An update on psoriasis ...
  • Vañó-Galván S, Gárate MT, Fleta-Asín B, et al. Analysis of ...
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of ...
  • Alfageme Roldán F, Bermejo Hernando A, Calvo González JL, Marqués ...
  • Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate ...
  • Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. ...
  • Mansouri Y, Goldenberg G. Biologic safety in psoriasis: Review of ...
  • Puig L, Julià A, Marsal S. The Pathogenesis and Genetics ...
  • Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, ...
  • Spandonaro F, Ayala F, Berardesca E, et al. The cost ...
  • Korman NJ, Zhao Y, Pike J, Roberts J, Sullivan E. ...
  • Schmitt J, Küster D. Correlation between Dermatology Life Quality Index ...
  • Chan B, Hales B, Shear N, et al. Work-related lost ...
  • Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. ...
  • Li K, Armstrong AW. A review of health outcomes in ...
  • Zhang W, Islam N, Ma C, Anis AH. Systematic review ...
  • Baker C, Mack A, Cooper A, et al. Treatment goals ...
  • Mrowietz U, Kragballe K, Reich K, et al. Definition of ...
  • Ministry Of Health. Surat Pekeliling Bil. ۱ Tahun ۲۰۱۴ - ...
  • Sulong S, Ismail A, Azizam NA, Md Nor N, Ahmed ...
  • Küster D, Nast A, Gerdes S, et al. Cost-effectiveness of ...
  • D’Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, ...
  • Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, ...
  • D’Souza LS, Payette MJ, Song M, Lim HW. Estimated cost ...
  • Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of ...
  • Sizto S, Bansback N, Feldman SRR, Willian MKK, Anis AHH. ...
  • Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. ...
  • Cabello Zurita C, Grau Pérez M, Hernández Fernández CP, et ...
  • Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, ...
  • Verma S, Dharmarajan S, Yang Y. PSS۱۲ modeling the cost-effectiveness ...
  • Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate ...
  • Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. ...
  • Salazar A, Aguirre A, Flores R. Cost-effectiveness analysis of ustekinumab ...
  • Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed ...
  • de Argila D, Rodríguez-Nevado I, Chaves a. Cost-Effectiveness Analysis Comparing ...
  • Colombo G, Altomare G, Peris K, et al. Moderate and ...
  • Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. ...
  • Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. ...
  • Augustin M, McBride D, Gilloteau I, O’Neill C, Neidhardt K, ...
  • Klijn SL, van den Reek JMPA, van de Wetering G, ...
  • Igarashi A, Kuwabara H, Fahrbach K, Schenkel B. Cost-efficacy comparison ...
  • Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, ...
  • Bronsard V, Paul C, Prey S, et al. What are ...
  • Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of ...
  • Riveros BS, Ziegelmann PK, Correr CJ. Cost-effectiveness of biologic agents ...
  • Cohen S, Baron S, Archer C, British Association of Dermatologists ...
  • Walsh JA, McFadden M, Woodcock J, et al. Product of ...
  • Mattei PLL, Corey KCC, Kimball ABB. Psoriasis Area Severity Index ...
  • Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI ...
  • Herédi E, Rencz F, Balogh O, et al. Exploring the ...
  • Driessen RJB, Bisschops LA, Adang EMM, Evers AW, Van De ...
  • Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment ...
  • نمایش کامل مراجع